RxDoctor Payments Data

Carmen Bautista-Dator, MD

Internal Medicine · Oswego, NYNPI 1346267291

Payments from drug & device makers

$3,239in general payments, 2019–2025

Across 186 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$575
  • GSK$433
  • Pfizer$312
  • Mannkind Corporation$300
  • AstraZeneca$273
  • Xeris Pharmaceuticals, Inc.$140
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,239 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$210,279
Medicare patients
232
Services billed
2,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$79,090
RybelsusSemaglutide38$63,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$53,516
XareltoRivaroxaban47$50,026
EliquisApixaban41$34,859
JanuviaSitagliptin Phosphate37$29,362
JardianceEmpagliflozin16$20,547
Breo ElliptaFluticasone/Vilanterol33$13,678
MyrbetriqMirabegron16$11,434
EntrestoSacubitril/Valsartan17$10,800
Combivent RespimatIpratropium/Albuterol Sulfate13$10,023
SymbicortBudesonide/Formoterol Fumarate12$5,388
Atorvastatin Calcium579$4,488
SynthroidLevothyroxine Sodium67$4,315
Albuterol Sulfate HfaAlbuterol Sulfate127$3,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$575$142,299123 claims
GSKTrelegy Ellipta, Breo Ellipta$433$67,19495 claims
PfizerEliquis$312$34,85941 claims
Boehringer IngelheimJardiance, Combivent Respimat$34$30,57029 claims
MerckJanuvia$52$29,36237 claims
NovartisEntresto$98$10,80017 claims
AstraZenecaSymbicort$273$5,38812 claims
AbbVieSynthroid$107$4,31567 claims
Arbor Pharmaceuticals, Inc.Edarbi$35$3,69513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Oswego

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →